Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott grows in emerging markets

This article was originally published in The Tan Sheet

Executive Summary

Abbott's worldwide nutrition sales jump 11.8 percent to $1.32 billion in the first quarter, benefiting from foreign exchange and continued growth in emerging markets. International nutritional sales climbed 18.1 percent to $678 million in the January-March period, while the U.S. grew 5.9 percent to $642 million, the Abbott Park, Ill., firm reported April 21. Sales of adult nutrition brands, including Ensure and Glucerna, climbed 10.3 percent in the U.S. and 20.6 percent internationally. VP of Investor Relations John Thomas said in an earnings call. Abbott Nutrition in China is growing twice the market rate. While Abbott's deal to buy Wockhardt's Indian nutritional business was called off, Abbott likely seeks other nutritional opportunities in India (1"The Tan Sheet" April 5, 2010). In the quarter, the company recorded total sales of $7.7 billion, a 14.6 percent gain over the year-ago quarter

You may also be interested in...

Abbott, Wockhardt Terminate Nutritional Business Deal

Pharmaceuticals and diagnostics giant Abbott and debt-ridden Indian drug maker Wockhardt call off their $130 million deal for a nutritional business announced less than a year ago

Coronavirus Update: US Public Confidence In COVID-19 Vaccines Declines

Confidence in the vaccine has slipped in the US, regardless of political affiliation.

J&J COVID Vaccine: Single-Dose Format Will ‘Expedite’ Phase III Trial

Effectiveness can be evaluated more quickly because researchers won’t have to wait for the second dose, company executive notes during briefing on the launch of the Phase III study.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts